Recombinant RSV Prefusion F-trimer Protein (strain A2)
Cat# DRA230-50ug
Size : 50ug
Brand : Novoprotein
Description Recombinant RSV (strain A2) Prefusion F-trimer Protein is produced by our Mammalian expression system and the target gene encoding Gln26-Leu513 is expressed with a 6His tag at the C-terminus. Some mutations and furin cleavage site substitutions are introduced to stabilize the trimeric prefusion state of RSV Fusion glycoprotein and abolish the furin cleavage site, respectively.
Accession ACO83301.1
Known As RSV F Protein; Respiratory syncytial virus Fusion glycoprotein
Mol Mass 56.1 kDa
APMol Mass 54-70 kDa, reducing conditions
Formulation Description Supplied as a 0.2 μm filtered solution of 20mM His-HCl, 10 % trehalose, 0.02% Tween 80,pH5.5.
Purity-SEC-HPLC 
Greater than 95% as determined by SEC-HPLC.(QC verified) Purity-SEC-HPLC Greater than 95% as determined by SEC-HPLC.(QC verified) Bioactivity-ELISA 
Immobilized RSV F antibody (AM14) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 4.29 ng/ml. (Regularly tested)
Immobilized RSV F antibody (AM14) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 4.29 ng/ml. (Regularly tested)
Immobilized RSV F antibody (MPE8) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 11.92 ng/ml. (Regularly tested)
Immobilized RSV F antibody (Motavizumab) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 4.9 ng/ml. (Regularly tested)
Immobilized RSV F Antibody (11A9)(DA091) at 2μg/ml (100μl/well ) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) .The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) is 4.37 ng/ml. (Regularly tested)
Immobilized Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) at 2μg/ml (100 μl/well) can bind RSV F Antibody (11A9)(DA091).The ED50 of RSV F Antibody (11A9)(DA091) is 5.36 ng/ml. (Regularly tested)
Immobilized RSV F antibody (AM14) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 4.29 ng/ml. (Regularly tested)
Immobilized RSV F antibody (D25) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 4.28 ng/ml. (Regularly tested)
Immobilized RSV F Antibody (11A9)(DA091) at 2μg/ml (100μl/well ) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) .The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) is 4.37 ng/ml. (Regularly tested)
Immobilized Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) at 2μg/ml (100 μl/well) can bind RSV F Antibody (11A9)(DA091).The ED50 of RSV F Antibody (11A9)(DA091) is 5.36 ng/ml. (Regularly tested)
Immobilized RSV F antibody (MPE8) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 11.92 ng/ml. (Regularly tested)
Immobilized RSV F antibody (Motavizumab) at 2μg/ml (100 μl/well) can bind Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230). The ED50 of Recombinant RSV Prefusion F-trimer Protein (strain A2) (DRA230) is 4.9 ng/ml. (Regularly tested) Bioactivity-BLI 
Loaded RSV F Antibody (11A9)(DA091) on Protein A Biosensor, can bind Recombinant RSV Prefusion F-trimer Protein (strain A2)(DRA230) with an affinity constant of 0.13 nM as determined in BLI assay. (Regularly tested) Bioactivity-Western Blot 
Bioactivity-Flow Cytometry 
5e5 of 293T cells transfected with RSV-preF full length LNP-mRNA were incubated with 100 μL of 10 μg/mL of anti-RSV-F antibody (human IgG) (Cat. No.: DA091) prior to staining with APC-conjugated anti Human IgG (Fig.C) and negative isotype control antibody (Fig.B), and non-transfected 293T cells were used as a control (Fig.A), binding activity was analyzed with APC signal. (QC tested) Storage - Reconstituted protein solution should be stored at ≤ -20°C.
- Stable for at least 24 months when stored as instructed.
Shipping The product is shipped on dry ice pack.Upon receipt, store it immediately at the temperature listed below.
Background Respiratory syncytial virus (RSV) is a highly contagious pathogen of the respiratory tract, primarily in infants and the elderly. A vaccine against RSV is currently not available, but is desired due to the high disease burden.RSV has two major surface glycoproteins (G and F) that play important roles in the initial stages of the infectious cycle. The RSV fusion glycoprotein (RSV F) is an attractive vaccine antigen, since it is the principal target of RSV neutralizing antibodies in human sera. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable postfusion conformation. Like other class I fusion proteins, the inactive precursor, RSV F0, requires cleavage during intracellular maturation by a furin-like protease. RSV F contains two furin sites, which leads to three polypeptides: F2, p27 and F1, with the latter containing a hydrophobic fusion peptide at its N terminus. An RSV F protein that has both high expression levels and maintains a stable prefusion conformation would be a promising subunit vaccine candidate against RSV. Thus we need stabilizing mutations of the prefusion instability.